Cargando…
TNFR2: The new Treg switch?
Three recent publications identified the TNF/TNR2 pathway as a new target to reduce graft-versus-host-disease through regulatory T cells activation or to potentially switch on a strong anti-leukemic effect through regulatory T cells blockade in allogeneic hematopoietic stem cell transplantation. Thi...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739577/ https://www.ncbi.nlm.nih.gov/pubmed/29296530 http://dx.doi.org/10.1080/2162402X.2017.1373236 |
| _version_ | 1783287892866498560 |
|---|---|
| author | Cohen, José L. Wood, Kathryn J. |
| author_facet | Cohen, José L. Wood, Kathryn J. |
| author_sort | Cohen, José L. |
| collection | PubMed |
| description | Three recent publications identified the TNF/TNR2 pathway as a new target to reduce graft-versus-host-disease through regulatory T cells activation or to potentially switch on a strong anti-leukemic effect through regulatory T cells blockade in allogeneic hematopoietic stem cell transplantation. This identified the TNF/TNR2 pathway as a swith and as a new target for immune checkpoint therapy to modulate the immune regulation in this clinical setting. |
| format | Online Article Text |
| id | pubmed-5739577 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-57395772018-01-02 TNFR2: The new Treg switch? Cohen, José L. Wood, Kathryn J. Oncoimmunology Point of View Three recent publications identified the TNF/TNR2 pathway as a new target to reduce graft-versus-host-disease through regulatory T cells activation or to potentially switch on a strong anti-leukemic effect through regulatory T cells blockade in allogeneic hematopoietic stem cell transplantation. This identified the TNF/TNR2 pathway as a swith and as a new target for immune checkpoint therapy to modulate the immune regulation in this clinical setting. Taylor & Francis 2017-09-21 /pmc/articles/PMC5739577/ /pubmed/29296530 http://dx.doi.org/10.1080/2162402X.2017.1373236 Text en © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
| spellingShingle | Point of View Cohen, José L. Wood, Kathryn J. TNFR2: The new Treg switch? |
| title | TNFR2: The new Treg switch? |
| title_full | TNFR2: The new Treg switch? |
| title_fullStr | TNFR2: The new Treg switch? |
| title_full_unstemmed | TNFR2: The new Treg switch? |
| title_short | TNFR2: The new Treg switch? |
| title_sort | tnfr2: the new treg switch? |
| topic | Point of View |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739577/ https://www.ncbi.nlm.nih.gov/pubmed/29296530 http://dx.doi.org/10.1080/2162402X.2017.1373236 |
| work_keys_str_mv | AT cohenjosel tnfr2thenewtregswitch AT woodkathrynj tnfr2thenewtregswitch |